Global Spinal Muscular Atrophy (SMA) Treatment Market – Industry Trends and Forecast to 2030

Spinal Muscular Atrophy (SMA) Treatment Market Analysis and Size

The market is primarily enhanced by the increasing incidence of spinal muscular atrophy (SMA). As per the National Organization for Rare Disorders (NORD), spinal muscular atrophy (SMA) affects almost 1 in 10,000 people worldwide. The rise in several initiatives to enhance treatment options for rare diseases and increasing demand for drugs, including nusinersen, onasemnogene abeparvovec, and others, helps uplift the market growth.

Data Bridge Market Research analyses that the spinal muscular atrophy (SMA) treatment market, which was USD 4,623.46 million in 2022, would rise to USD 18,718.08 million by 2030 and is expected to undergo a CAGR of 19.10% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Spinal Muscular Atrophy (SMA) Treatment Market Scope and Segmentation

Market Definition

Spinal muscular atrophy (SMA) is a type of autosomal recessive neurodegenerative genetic disorder usually characterized by muscle weakening and atrophy. The condition occurs due to the mutation in the survival motor neuron. Several patients suffering from spinal muscular atrophy possess issues in walking, standing, and controlling their head movements.   

Global Spinal Muscular Atrophy (SMA) Treatment Market Dynamics

Drivers

• Increasing Awareness About the Novel Therapies of SMA

The increasing awareness of novel therapies is a major factor leading to market growth. For instance, Cure SMA organized the 2022 Annual SMA Conference in Anaheim to reunite the SMA community, including patients, researchers, their caregivers, and clinicians, in 2021. Under this conference, various activities were performed, including educational workshops and social activities. Such conferences offer opportunities for manufacturers to connect and interact with SMA people and understand their unmet treatment needs. This factor boosts the growth of the market.

• Increasing Demand for Spinraza

The increasing demand for Spinraza is boosting market growth. Spinraza is a prescription medicine used for treating pediatric and adult patients. It is administrated through intrathecal injection by experienced healthcare providers. Spinraza is fully reimbursed globally by a few countries, such as Norway, Italy, Netherlands, Croatia, and Poland. Thus, this factor help in the market growth.

Opportunities

• Increasing Effects of Gene Replacement Therapy

The effects of gene replacement therapy are long-lasting and enhance the quality of life by eliminating genetic disorders. Lately, the U.S. FDA approved Zolgensma for treating spinal muscular atrophy as a gene therapy in 2019, which is found to be the most effective in results, and many other drugs are in the pipeline. Therefore, the high use of gene replacement therapy for treating these patients is on the rise. Thus, this factor boosts market growth.  

• Increasing Strategic Developments Associated with Spinal Muscular Atrophy (SMA) Treatment

Numerous market players are adopting varied strategies, such as mergers and acquisitions, to grow the market. For instance, Biogen and Ionis Pharmaceuticals, Inc., entered into a licensing agreement to develop another experimental drug BIIB115 for treating patients with SMA in 2022. BIIB115 is an experimental preclinical-stage drug. Therefore, this factor acts as a major factor that increases market growth.

Restraints/Challenges

• Low Success Rates of Drugs

Developing several new products is challenging for new market players because of the low success rate in clinical trials. As per the National Library of Medicine, the clinical trial success rate is 10% while developing new SMA drugs. For instance, F. Hoffmann-La Roche Ltd stopped the clinical development program for Olesoxim since the product failed to offer benefits to type 2 & 3 SMA patients in 2020. Therefore, the low success rate in clinical trials creates uncertainty among new market players to invest in new drug development, impeding market growth.  

This spinal muscular atrophy (SMA) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the spinal muscular atrophy (SMA) treatment market, contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2021, Novartis announced the lift of a part of a clinical trial and planned to start a new, pivotal Phase 3 study of intrathecal OAV-101 in elderly patients suffering from spinal muscular atrophy. 

Global Spinal Muscular Atrophy (SMA) Treatment Market Scope

The spinal muscular atrophy (SMA) treatment market is segmented on the basis of drugs, type, treatment, route of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug

• Nusinersen
• Onasemnogene
• Abeparvovec
• Others

Type

• Werdnig-Hoffmann Disease
• Infant SMA
• Kugelberg-Welander Disease
• Adult SMA

Treatment

• Medication
• Physical Therapy
• Surgery
• Others

Route of Administration

• Intrathecal
• Intraspinal
• Subcutaneous
•  Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Spinal Muscular Atrophy (SMA) Treatment Market Regional Analysis/Insights

The spinal muscular atrophy (SMA) treatment market is analyzed and market size insights and trends are provided by drugs, type, treatment, route of administration, distribution channel and end user as referenced above.

The countries covered in the spinal muscular atrophy (SMA) treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to grow during the forecast period in the spinal muscular atrophy (SMA) treatment market because of the large patient population that exists in the region. Also, the region's growth is because of the entry of new market players.

North America dominates the market in the forecast period due to the region's huge presence of advanced healthcare systems. Also, the increasing incidence of SMA disorders and increased expenditure on treatment products are the primary factors for the region's dominance.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The spinal muscular atrophy (SMA) treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for spinal muscular atrophy (SMA) treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the spinal muscular atrophy (SMA) treatment market. The data is available for historic period 2011-2021.

Competitive Landscape and Spinal Muscular Atrophy (SMA) Treatment Market Share Analysis

The spinal muscular atrophy (SMA) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to spinal muscular atrophy (SMA) treatment market.

Some of the major players operating in the spinal muscular atrophy (SMA) treatment market are:

• Sanofi (France)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Boehringer Ingelheim International GmbH. (Germany)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Biogen (U.S.)
• Pfizer Inc. (U.S.)
• Ionis Pharmaceuticals, Inc. (U.S.)
• Regeneron Pharmaceuticals Inc (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Novo Nordisk A/S (Denmark)
• Takeda Pharmaceutical Company Limited (Japan)
• AstraZeneca (U.K.)
• Leadiant Biosciences, Inc.(Italy)
• Catalyst Pharmaceuticals, Inc.(U.S.)
• PTC Therapeutics (U.S.)

SKU-50476